Figure 1A


Best % Change from Baseline in Sum of Diameters
120
100
80
60
40
20
0
–20
–40
–60
–80
–100
–120
Cohort
0.003 mg (N = 1)
0.01 mg (N = 1)
0.03 mg (N = 1)
0.1 mg (N = 1)
0.3 mg (N = 9)
1 mg (N = 8)
3 mg (N = 9)†
10 mg (N = 16)†
30 mg (N = 7)†
100 mg (N = 13)†
100 mg (dose expansion) (N = 28)†

Figure 1B


First response (PR or Better)
Disease progression
Ongoing treatment
Death
0
10
20
30
40
50
60
70
80
90
100
Duration of Treatment (Weeks)
0.3 mg (N = 1)
1 mg (N = 1)
3 mg (N = 4)†
10 mg (N = 6)†
30 mg (N = 1)†
100 mg (N = 4)†
100 mg (dose expansion) (N = 8)†

Figure 2A


Tarlatamab (N = 107), Median: 3.7, 95% CI: (2.1, 5.4)
Probability of Progression-Free Survival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
2
4
6
8
10
12
14
16
18
20
Months
Number of Patients at Risk
107
57
38
28
22
17
14
8
6
2
0

Figure 2B


Tarlatamab (N = 107), Median: 13.2, 95% CI: (10.5, –)
Probability of Overall Survival
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0
2
4
6
8
10
12
14
16
18
20
22
24
Months
Number of Patients at Risk
107
91
76
61
52
44
33
15
14
9
4
1
0

Figure 3


True positive rate
1.00
0.75
0.50
0.25
0.00
0.00
0.25
0.50
0.75
1.00
False positive rate

Figure 4



Figure 5A


Cohorts 6-10, 30
Confirmed.BOR
NE
SD
CR
PD
PR
NA
R = −0.41, p = 0.00046
Percent change in SLD from baseline
50
0
-50
-100
0
25
50
75
100
Percent DLL3+ tumor cells at baseline (overall)

Figure 5B


Cohorts 6-10, 30
Confirmed.BOR
NE
SD
CR
PD
PR
NA
R = −0.44, p = 0.00013
Percent change in SLD from baseline
50
0
-50
-100
0
25
50
75
100
Percent DLL3+ tumor cells at baseline (3+)

Figure 6A



Figure 6B



Figure 6C



Figure 6D



Figure 7


G = 0
G ≥ 1
40
45
40
45
256
16
1
IL-10, pg/mL
C1D1 Pretreatment
Post C1D1 Peak
Time

Figure 8A



Figure 8B



Figure 9

CXDX

(day X; IV = intravenous; Q2W = every 2 weeks

Study

- Sc
- Tr

:

: up to 21 days before enrollment

t: treatment continues until confirmed radiographic progression or disease progression

- En

atment: upon permanent discontinuation from treatment, visit should occur as soon as possible after the last dose of AMG 757

- Sa

ow-up: 42 (± 5) days from the last dose of AMG 757.

- Lo

l follow-up: every 3 months up to 1 year from the last subject's last dose of AMG 757 or 5 years from first subject enrolled, whichever occurs first.

As

nts may be performed by clinic visit, telephone, or chart review

Figure 10


3D Waterfall-Swimmer Plot for NEPC DLL3 Positive (N=17)
Tumor size change (%)
100
90
80
70
60
50
40
30
20
10
0
-10
-20
-30
-40
-50
-60
-70
-80
91.9
90
59.8
27.8
15.3
15
-14.3
-27.2
-27.3
-31.9
30% Reduction
-50.4
-55.6
-62.7
-68.1
-72.2
SLD (mm)
Duration on Treatment (Months)
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
PD
PR
SD
Treatment Ongoing
Objective Response